Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4386-4393

  Patel, Heena ^a   Andresen, Arne ^a   Vente, Andreas ^a   Heilmann, Hans Dietrich ^a   Stubbings, Will ^a   Seiberling, Michael ^b   Lopez Lazaro, Luis ^b   Pokorny, Rolf ^b   Labischinski, Harald ^a  

^a MerLion Pharmaceuticals GmbH   (Germany)

^b Covance Clinical Research Unit AG ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; FINAFLOXACIN; GAMMA GLUTAMYLTRANSFERASE; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; FLATULENCE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; DOUBLE-BLIND METHOD; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED;

EID: 80051811622     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00832-10     Document Type: Article

References (15)

1. Buissonnière, A., et al. 2008. Antimicrobial activity of finafloxacin (FIN) against Helicobacter pylori in vitro and in vivo, poster F1-2038. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA), 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
2. Chien, S-C, et al. 1997. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41:2256-2260. (Pubitemid 27422222)
3. Dalhoff, A, and F-J Schmitz. 2003. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 22:203-221. (Pubitemid 36578906)
4. Dalhoff, A., W. Stubbings, and S. Schubert. 2011. Comparative in vitro activities of the novel antibacterial finafloxacin against selected gram-positive and gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine. Antimicrob. Agents Chemother. 55:1814-1818.
5. Endermann, R., C. Ladel, W. Stubbings, and H. Labischinski. 2008. Pharmacokinetics (PK) and in vivo efficacy of oral finafloxacin (FIN) and comparators in rodent models of systemic infection, poster F1-2044. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
6. Endermann, R., C. Ladel, W. Stubbings, and H. Labischinski. 2008. In vivo efficacy of finafloxacin in difficult to treat animal models of infection, poster F1-2045. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA), 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
7. Goh, C Y, F. Goh, W. Stubbings, H-P Kroll, and H. Labischinski. 2008. Bactericidal activity of finafloxacin against difficult to kill growth forms of Escherichia coli, poster F1-2042. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA), 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
8. Gonzalez, M A, et al. 1984. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob. Agents Chemother. 26:741-744. (Pubitemid 15211673)
9. Hooper, D C, and E. Rubinstein. 2003. Quinolone antimicrobial agents, 3rd ed. ASM Press, Washington, DC.
10. Kresken, M., B. Körber-Irrgang, H. Labischinski, and W. Stubbings. 2008. Effect of pH on the in vitro activity of finafloxacin against gram-negative and gram-positive bacteria, poster F1-2037. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA), 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
11. Patel, H., et al. 2008. A phase I study to determine safety, tolerability and pharmacokinetics (PK) of finafloxacin (FIN) in healthy subjects, poster F1-2048. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
12. Schmuck, G., G. Wasinska-Kempka, A. Vente, and H. Labischinski. 2008. In vitro toxicological profiling of finafloxacin, poster F1-2047. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA), 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
13. Schubert, S., W. Stubbings, and A. Dalhoff. 2008. Comparative inhibitory and bactericidal activities of finafloxacin and ciprofloxacin against gram-negative and gram-positive UTI-pathogens under physiological conditions and at varying pH-values. Poster F1-2041. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA), 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
14. Stass, H., A. Dalhoff, D. Kubitza, and U. Schühly. 1998. Pharmacokinetics, safety and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents Chemother. 42:2060-2065. (Pubitemid 28363093)
15. Wagenlehner F M, et al. 2011. Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose. Chemotherapy 57:97-107.